Johnson & Johnson Forecasts 9.8% Revenue Growth, Supports 21% Valuation Upside
LLY•Johnson & Johnson’s Innovative Medicine segment grew 7.4% this quarter despite a 920-basis-point STELARA headwind, driving double-digit sales excluding the legacy drug. A three-year model forecasts 9.8% revenue growth, margins rising to 23.4% and earnings climbing from $21.0B to $29.9B, implying a 21% valuation gain to $693.8B market cap.
1. Segment Growth Performance
Johnson & Johnson’s Innovative Medicine segment overcame a 920-basis-point STELARA patent cliff headwind to post 7.4% growth this quarter. Excluding the legacy drug, overall company revenue rose in double digits, highlighting the underlying strength of newer products in the pipeline.
2. Three-Year Financial Model
A conservative scenario projects revenue compounding at 9.8% annually over three years, with margins drifting from 21.8% to 23.4%. This drives earnings from $21.0B to $29.9B as the company sustains its recovery momentum.
3. Valuation Implications
The model applies a P/E multiple moving from 27.3x toward a 23.2x mid-point, trimming roughly 15% off earnings growth before valuation. That adjustment implies a valuation increase of about 21%, raising market cap from $574.1B to $693.8B.
4. New Product Catalyst
ICOTYDE, an oral peptide for psoriatic disease, is expected to become a major growth driver. Early uptake shows prescriptions for roughly 1,500 patients since launch, indicating potential to accelerate top-line momentum.
